/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
MONTREAL, Oct. 24, 2013 /CNW Telbec/ - OPMEDIC GROUP INC. ("OPMEDIC GROUP" or the "Corporation") (TSX: OMG), issue a reminder that a Special Meeting of Shareholders will be held in the Offices of Norton Rose Fulbright Canada LLP, 1 Place Ville Marie, Suite 2500, Montreal, Quebec, H3B 1R1, on Friday, November 1, 2013, at 9:00 a.m. Eastern Time.
The Special Meeting will consider resolutions set forth in the Management Information Circular dated October 3, 2013 with respect to the proposed amalgamation (the "Transaction") of the Corporation with Kemourmedic Acquisition Inc., a corporation indirectly owned and controlled by Drs. Pierre St-Michel, Marc Villeneuve and Jean-Yves Fontaine.
Registered shareholders are reminded that the cut-off time for submitting proxies in order to vote on the Transaction is 5:00 p.m., Eastern time, on Wednesday, October 30, 2013. Beneficial shareholders who hold their shares in brokerage or investment accounts or through intermediaries may have an earlier cut-off date to submit their votes through their voting instruction form.
A copy of the Management Information Circular, the form of proxy and related documents are accessible on SEDAR at www.sedar.com. Registered shareholders who have questions should contact the Corporation's registrar and transfer agent and the depositary for the Transaction, Computershare Investor Services Inc., at tel. 1-800-564-6253, or by e-mail: email@example.com. Beneficial or non-registered shareholders should contact their broker, dealer, custodian or other intermediary that administers the account in which their shares are held.
About OPMEDIC GROUP
OPMEDIC GROUP is a company incorporated under the laws of the Province of Quebec which provides healthcare-related services including surgical and endoscopic facilities and services to patients and surgeons (with its OPMEDIC division), fertility treatments, medical imaging, laboratory services and diagnostic procedures (with its PROCREA Cliniques division, its subsidiary 8362556 Canada Inc. and a joint venture 7667264 Canada Inc.) and sperm banking services (with its PROCREA Cryopreservation Centre subsidiary). OPMEDIC GROUP's Common Shares trade on the TSX under the symbol "OMG".
This press release may contain certain "forward‐looking statements". Forward‐looking statements are subject to certain risks and uncertainties, many of which are beyond the Corporation's control. There can be no assurance that such statements will prove to be accurate. Consequently, actual results and future events may differ materially from those anticipated by such statements. Readers should not rely unduly on such forward‐ looking statements. The risks and uncertainties include, but are not limited to, the satisfaction of the conditions to consummate the Transaction, including the approval of the Transaction by the shareholders, the occurrence of any event, change or other circumstances that could give rise to termination of the Transaction, a delay in the consummation of the Transaction or failure to complete the Transaction for any other reason, the amount of the costs, fees, expenses and charges related to the Transaction, and the risks associated with general economic conditions. The forward‐looking statements in this press release are made as of the date of this press release and, except as required by law, OPMEDIC GROUP disclaims any obligation to update or revise publicly any forward‐looking statements, whether as a result of new information or future events.
The content of this press release has not been approved by nor submitted to the TSX which assumes no liability therefor.
SOURCE: OPMEDIC GROUP INC.
For further information:
Vice President Finance and Chief Financial Officer
(514) 345-8535, x 2260